Heart Failure

View the latest content related to this topic

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

L.A. McKeown

November 04, 2025

Slides

See all

Presentation ESC 2025

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Presenter: David D. Berg

August 30, 2025

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

Presentation ESC 2025

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Presenter: Faiez Zannad

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

Presentation ACC 2025

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

Presenter: Stefan D. Anker

March 30, 2025

News

See all

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

By Michael O'Riordan

November 05, 2025

News Daily News

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

By L.A. McKeown

November 04, 2025

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

By Michael O'Riordan

October 27, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

By L.A. McKeown

October 25, 2025

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

By Michael O'Riordan

October 17, 2025

ACC 2025

March 29

March 31, 2025

CTO 2025

February 28

March 01, 2025

THT 2025

February 11

February 13, 2025

Videos on This Topic

See all

Advertisement

Heart Failure

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

Slides

DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

FAIR-HF2 Trial: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality

News

What’s Going to Be Hot at AHA 2025?

PREVENT-TAHA8: Post-MI Intracoronary Stem Cells May Lower HF Risk After STEMI

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

October 2025 Dispatch for the CV Team

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

More on This Topic

Conference Coverage

ACC 2025

CTO 2025

THT 2025

Videos on This Topic

Advertisement

Heart Failure

Slides

News

More on This Topic

Conference Coverage

Videos on This Topic

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content